BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 29520555)

  • 1. Financial impact of intravenous iron treatments on the management of anaemia inpatients: a 1 year observational study.
    Delpeuch A; Ruivard M; Abergel A; Aumaitre O; Boisgard S; Bagel S; Sautou V
    Int J Clin Pharm; 2018 Jun; 40(3):686-692. PubMed ID: 29520555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An analysis of the health service efficiency and patient experience with two different intravenous iron preparations in a UK anaemia clinic.
    Wilson PD; Hutchings A; Jeans A; Macdougall IC
    J Med Econ; 2013; 16(1):108-14. PubMed ID: 22989163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and cost effectiveness of intravenous ferric carboxymaltose versus iron sucrose in adult patients with iron deficiency anaemia.
    Basha A; Ibrahim MIM; Hamad A; Chandra P; Omar NE; Abdullah MAJ; Aldapt MB; Hussein RM; Mahfouz A; Adel AA; Shwaylia HM; Ekeibed Y; AbuMousa R; Yassin MA
    PLoS One; 2021; 16(8):e0255104. PubMed ID: 34375369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
    Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
    Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A fast-track anaemia clinic in the Emergency Department: cost-analysis of intravenous iron administration for treating iron-deficiency anaemia.
    Quintana-Díaz M; Muñoz-Romo R; Gómez-Ramírez S; Pavía J; Borobia AM; García-Erce JA; Muñoz M
    Blood Transfus; 2017 Sep; 15(5):438-446. PubMed ID: 28151394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic Evaluation of Ferric Carboxymaltose for the Management of Hemodialysis Patients with Iron Deficiency Anemia in Italy.
    Rognoni C; Ortalda V; Biasi C; Gambaro G
    Adv Ther; 2019 Nov; 36(11):3253-3264. PubMed ID: 31489572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized controlled trial comparing ferric carboxymaltose and iron sucrose for treatment of iron deficiency anemia due to abnormal uterine bleeding.
    Mahey R; Kriplani A; Mogili KD; Bhatla N; Kachhawa G; Saxena R
    Int J Gynaecol Obstet; 2016 Apr; 133(1):43-8. PubMed ID: 26868063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.
    Pollock RF; Muduma G
    Adv Ther; 2018 Dec; 35(12):2128-2137. PubMed ID: 30456520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Prospective Randomised Controlled Trial of a Single Intravenous Infusion of Ferric Carboxymaltose vs Single Intravenous Iron Polymaltose or Daily Oral Ferrous Sulphate in the Treatment of Iron Deficiency Anaemia in Pregnancy.
    Khalafallah AA; Hyppa A; Chuang A; Hanna F; Wilson E; Kwok C; Yan C; Gray Z; Mathew R; Falloon P; Dennis A; Pavlov T; Allen JC
    Semin Hematol; 2018 Oct; 55(4):223-234. PubMed ID: 30502851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom.
    Pollock RF; Muduma G
    J Med Econ; 2020 Jul; 23(7):751-759. PubMed ID: 32208038
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of a multifaceted intervention to promote the use of intravenous iron sucrose complex instead of ferric carboxymaltose in patients admitted for more than 24 h.
    Touchard J; Perrin G; Berdot S; Pouchot J; Loustalot MC; Sabatier B
    Eur J Clin Pharmacol; 2021 Feb; 77(2):189-195. PubMed ID: 32926203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of ferric carboxymaltose compared to iron sucrose in women with iron deficiency anemia: phase IV clinical trials.
    Naqash A; Ara R; Bader GN
    BMC Womens Health; 2018 Jan; 18(1):6. PubMed ID: 29304848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment.
    Pollock RF; Muduma G
    Expert Rev Hematol; 2019 Feb; 12(2):129-136. PubMed ID: 30689458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose or oral iron as preoperative treatment in patients with colon cancer and iron deficiency anaemia.
    Calvet X; Gené E; ÀngelRuíz M; Figuerola A; Villoria A; Cucala M; Mearin F; Delgado S; Calleja JL
    Technol Health Care; 2016; 24(1):111-20. PubMed ID: 26409561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Iron substitution in outpatients in Switzerland: Increase of costs associated with intravenous administration].
    Giger M; Achermann R
    Z Evid Fortbild Qual Gesundhwes; 2013; 107(4-5):320-6. PubMed ID: 23916272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective review of effectiveness and safety of intravenous ferric carboxymaltose given to children with iron deficiency anaemia in one UK tertiary centre.
    Tan MLN; Windscheif PM; Thornton G; Gaynor E; Rodrigues A; Howarth L
    Eur J Pediatr; 2017 Oct; 176(10):1419-1423. PubMed ID: 28844092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The health care cost of intravenous iron treatment in IBD patients depends on the economic evaluation perspective.
    Bager P; Dahlerup JF
    J Crohns Colitis; 2010 Oct; 4(4):427-30. PubMed ID: 21122539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
    Geisser P; Banké-Bochita J
    Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial.
    Onken JE; Bregman DB; Harrington RA; Morris D; Buerkert J; Hamerski D; Iftikhar H; Mangoo-Karim R; Martin ER; Martinez CO; Newman GE; Qunibi WY; Ross DL; Singh B; Smith MT; Butcher A; Koch TA; Goodnough LT
    Nephrol Dial Transplant; 2014 Apr; 29(4):833-42. PubMed ID: 23963731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous iron treatments for iron deficiency anemia in inflammatory bowel disease: a budget impact analysis of iron isomaltoside 1000 (Monofer) in the UK.
    Pollock RF; Muduma G
    Expert Opin Drug Deliv; 2017 Dec; 14(12):1439-1446. PubMed ID: 29032713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.